



NDA 021825

ACCELERATED APPROVAL

Cato Research
Attention: Lynda Sutton
U.S. Agent for ApoPharma, Inc
4364 South Alston Avenue
Durham, NC 27713-2220

Dear Ms. Sutton:

Please refer to your New Drug Application (NDA) dated January 29, 2009, received January 30, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ferriprox[®] (deferiprone) 500 mg Tablet.

We acknowledge receipt of your amendments dated February 25; April 14, 29; May 6 and 10; June 7, 14, and 22; July 11, 25, and 27; August 12, 19, 22, and 26; September 6, 16, 22, 26, and 29; October 3, 5, 7, 13, and 14, 2011.

The April 14, 2011 submission constituted a complete response to our November 30, 2009 action letter.

This new drug application provides for the use of Ferriprox[®] (deferiprone) Tablet for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 314.500), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text and required patient labeling. Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

Based on the stability data provided in your application, the drug product is granted a 24-month expiry when stored at USP controlled room temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

IMMEDIATE CONTAINER LABELS

Submit the final printed container label that is identical to the immediate container label submitted on October 13, 2011 as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 021825.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ACCELERATED APPROVAL REQUIREMENTS

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled clinical trials to verify and describe clinical benefit. We remind you of your postmarketing requirement specified in your submission dated October 13, 2011.

You are required to conduct such trials with due diligence. If postmarketing trials fail to verify that clinical benefit is conferred by deferiprone, or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530(b), withdraw or modify approval.

Granting of these approvals are contingent upon completion of clinical trials to verify the clinical benefit of deferiprone. These postmarketing trials are subject to the reporting requirements of 21 CFR 314.81.

This requirement, along with required completion dates, is listed below.

PMR 1828-1 Conduct a trial to determine the efficacy and safety of the use of deferiprone to treat iron overload in patients with sickle cell disease and transfusional hemosiderosis who have not been adequately treated with available chelating agents. Submit the protocol for review and concurrence prior to commencing. The trial will enroll a sufficient number of patients with sickle cell disease as described above, to provide sufficient evidence to assess the efficacy and safety in the sickle cell disease population described. The trial may enroll patients with other conditions who have developed transfusional iron overload. The trial will stratify for hematologic diagnosis for the randomization. The primary and secondary endpoints will measure changes in cardiac iron concentration and liver iron concentration.

Final Protocol Submission:	February 2012
Trial Completion:	January 2016
Final Report Submission:	July 2016

Submit final reports to this NDA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated "**Subpart H Postmarketing Requirement(s)**."

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess known serious risks for agranulocytosis.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

PMR 1828-2 Establish a registry in order to perform an enhanced pharmacovigilance study of agranulocytosis. Submit a protocol to establish the registry and describe procedures for this enhanced pharmacovigilance prior to commencing the study. Procedures should include: Creation of marketing materials to inform and encourage clinicians to report agranulocytosis events to the sponsor; monitoring of all reported cases and active follow-up to characterize the demographics, recent prior blood counts, concomitant medications, co-existing conditions, duration of drug exposure prior to onset, outcomes of the event, and other factors that may help to characterize the agranulocytosis event. Sponsor also will institute procedures to obtain blood samples from patients with reported cases of agranulocytosis to store for later analysis of possible genetic underlying factors that may predict the risk of agranulocytosis. Submit interim reports annually describing the above results.

Final Protocol Submission:	April 2012
Annual Interim Report #1:	April 2013
Annual Interim Report #2:	April 2014
Annual Interim Report #3:	April 2015
Annual Interim Report #4:	April 2016
Annual Interim Report #5:	April 2017
Annual Interim Report #6:	April 2018
Trial Completion:	October 2018
Final Report Submission:	April 2019

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to identify unexpected serious risks of QT prolongation, alterations in metabolism and drug effect related to hepatic or renal impairment.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

PMR 1828-3 Conduct a clinical trial per ICH E14 to assess the potential for deferiprone to prolong the QT interval. Submit the protocol for IRT review and concurrence prior to commencing.

Final Protocol Submission:	January 2012
Trial Completion:	July 2013
Final Report Submission:	December 2013

PMR 1828-4 Conduct a pharmacokinetic trial of both deferiprone and its primary 3-O-glucuronide metabolite in subjects with hepatic impairment. This pharmacokinetic trial should be conducted in a population with mild to severe hepatic insufficiency and the number of patients enrolled in the trial should be sufficient to detect PK differences. The subjects enrolled in this trial should have demographics that are representative of the indicated population (e.g., age, weight, gender, race). Submit the protocol for review and concurrence prior to commencing.

Final Protocol Submission: September 2012
Trial Completion: February 2014
Final Report Submission: July 2014

PMR 1828-5 Conduct a pharmacokinetic trial of both deferiprone and its primary 3-O-glucuronide metabolite in subjects with renal impairment. This pharmacokinetic trial should be conducted in a population with mild to severe renal insufficiency and the number of patients enrolled in the trial should be sufficient to detect PK differences. The subjects enrolled in this trial should have demographics that represent the indicated population (e.g., age, weight, gender, race) to the extent possible. Submit the protocol for review and concurrence prior to commencing.

Final Protocol Submission: September 2012
Trial Completion: February 2014
Final Report Submission: July 2014

Submit the protocols to your IND 045724, with a cross-reference letter to this NDA. Submit all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **“Required Postmarketing Protocol Under 505(o)”**, **“Required Postmarketing Final Report Under 505(o)”**, **“Required Postmarketing Correspondence Under 505(o)”**.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

PMC 1828-6 Conduct *in vitro* studies to determine the affect of moderate to strong UDP glucuronosyltransferase (UGT) inhibition and moderate to strong UGT induction

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.